This Series B round brings the company’s total funding to $223.5 million

Kidney care company Strive Health landed $140 million in a Series B funding led by Alphabet’s growth fund CapitalG, bringing its total funding to $223.5 million. The deal is expected to give the company “unique access” to Google and Alphabet assets.

Redpoint, NEA, Town Hall Ventures, Ascension Ventures and Echo Ventures also participated in the round.

The company’s platform is able to integrate chronic kidney disease and end-stage renal disease patient data from across various systems into one platform. The technology was deigned to help identify disease progression and make predictions about a patient’s condition.

The company pitches its tool as a way to help caregivers personalize care for each patient. The tool also enabled caregivers to communicate and share recommendations. Strive’s tool can also be used to help communicate transplants or home dialysis.

The new money will be put towards growing the company and go-to-market efforts.

“Our focus is on providing great patient care. Technology is a critical aspect of doing this well, and our unique partnership with CapitalG will help us profoundly elevate our growth and technology vision by leveraging the insights and expertise of the best and brightest minds at Google and Alphabet,”  Chris Riopelle, CEO of Strive Health, said in a statement.

“We are thrilled by how this partnership will take us to the next level and enable compassionate kidney care the way it should be done.”

Kidney disease is common in the U.S. In fact, 15% of adults in the U.S. have chronic kidney disease, according to the CDC.

Several digital health companies are working on tools to help address the condition. In August Renalytix AI announced a research partnership with AstraZeneca to develop and launch medical strategies for renal and metabolic diseases, as well as cardiovascular disease.

In 2019, Scanwell Health announced a partnership with the Chronic Renal Insufficiency Cohort (CRIC) Study, an ongoing investigation of chronic kidney disease and other comorbid conditions.

Chronic and end-stage kidney disease patients continue to be underserved by the current healthcare system. Strive has built an industry-leading kidney care solution that has the potential to transform patients’ lives,” Sumi Das, partner at CapitalG, said in a statement.

“After extensively studying the landscape, we determined that Strive’s technology, care delivery model, and team were best-in-class in the rapidly emerging kidney care segment. We are excited to partner with the Strive team to improve patient outcomes and significantly drive down healthcare costs.”